Dapson in Heterocyclic Chemistry Part VI: Synthesis and Molecular Docking of Some Novel Sulfonebiscompounds of Expected Anticancer Activity

M. M. Ghorab; M. S. Al-Said; Y. M. Nissan

doi:10.1055/s-0032-1323660

Arzneimittelforschung, Inhaltsverzeichnis

Arzneimittelforschung 2012; 62(11): 497-507
DOI: 10.1055/s-0032-1323660

Original Article

Dapson in Heterocyclic Chemistry Part VI: Synthesis and Molecular Docking of Some Novel Sulfonebiscompounds of Expected Anticancer Activity

M. M. Ghorab

¹Medicinal, Aromatic and Poisonous Plants Research Center (MAPPRC), College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

,

M. S. Al-Said

¹Medicinal, Aromatic and Poisonous Plants Research Center (MAPPRC), College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

,

Y. M. Nissan

²Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University

› Institutsangaben

Abstract

To discover new bioactive lead compounds for medicinal purposes, herein, sulfone biscompounds bearing dihydrothiazoles (3–9, 14, 15), acrylamide (11), thiazolidinones (12, 13, 20), thiophenes (16, 17) and benzothiophene (19) were prepared and tested for their anticancer activity. The structures of the products were confirmed from elemental analysis as well as spectral data. All the synthesized compounds showed remarkable anticancer activity against human breast cancer cell line especially, compound (3) with IC₅₀ value 23.02 µM which was better than that of Doxorubicin by three folds. In order to elucidate the mechanism of action of their cytotoxic activity molecular docking on the active sites of farnesyl transferase and arginine methyl transferase was performed for all synthesized compounds and good results were obtained.

Key words

thiazole - acrylamide - thiophene - benzothiophene - anticancer activity

Volltext

Referenzen

References
1 MacMahon JB, Gulakawski RJ, Weislow OS et al. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 754-760
2 Williams TM, Ciccarone TM, MacTough SC et al. 5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J Med Chem 1993; 36: 1291-1294
3 Corbett JW, Co SS, Rodgers JD et al. Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors. J Med Chem 2000; 43: 2019-2030
4 Richman D, Rosethal AS, Koog MS et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991; 35: 305-308
5 Dueweke TJ, Poppe SM, Romero DL et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993; 37: 1127
6 Young SD, Britcher SF, Tran LE et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995; 39: 2602-2605
7 Young SD, Amblard MC, Brichter SF et al. 2-Heterocyclic indole-3-sulfones as inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 1995; 5: 491-496
8 Artico M, Silvestri R, Stefancich G et al. Synthesis of pyrryl aryl sulfones targeted at the HIV-1 reverse transcriptase. Arch Pharm (Weinheim) 1995; 328: 223-229
9 Bissinger E, Heinke R, Spannhoff A et al. Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg Med Chem 2011; 19: 3717-3731
10 Bondock S, Fadaly W, Metwally MA. Synthesis and antimicrobial activity of some new thiazole, thiophene and pyrazole derivatives containing benzothiazole moiety. Eur J Med Chem 2010; 45: 3692-3701
11 Bellina F, Cauteruccio S, Rossi R. Synthesis and biological activity of vicinal diaryl-substituted 1H-imidazoles. Tetrahedron 2007; 63: 4571-4624
12 Konstantinova LS, Bol’shakov OI, Obruchnikova NV et al. One-pot synthesis of 5-phenylimino, 5-thieno or 5-oxo-1,2,3-dithiazoles and evaluation of their antimicrobial and antitumor activity. Bioorg Med Chem Lett 2009; 19: 136-141
13 Bellina F, Rossi R. Synthesis and biological activity of pyrrole, pyrroline and pyrrolidine derivatives with two aryl groups on adjacent positions. Tetrahedron 2006; 62: 7213-7256
14 Gottumukkala AL, Derridj F, Djebbar S et al. Alkenyl bromides: useful coupling partners for the palladium-catalysed coupling with heteroaromatics via a C–H bond activation. Tetrahedron Lett 2008; 49: 2926-2930
15 Tegley CM, Viswanadhan VN, Biswas K et al. Discovery of novel hydroxy-thiazoles as HIF-α prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation. Bioorg Med Chem Lett 2008; 18: 3925-3928
16 Hayakawa M, Kaizawa H, Kawaguchi K et al. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2007; 15: 403-412
17 Isloor AM, Kalluraya B, Pai KS. Synthesis, characterization and biological activities of some new benzo[b]thiophene derivatives. Eur J Med Chem 2010; 45: 825-830
18 Boateng CA, Eyunni SVK, Zhu XY et al. Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens. Bioorg Med Chem 2011; 19: 458-470
19 Al-Said MS, Bashandy MS, Al-qasoumi SI et al. Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives. Eur J Med Chem 2011; 46: 137-141
20 Jarak I, Kralj M, Piantanida I et al. Novel cyano- and amidino-substituted derivatives of thieno[2,3-b]- and thieno[3,2-b]thiophene-2-carboxanilides and thieno[3′,2′:4,5]thieno- and thieno[2′,3′:4,5]thieno [2,3-c]quinolones: Synthesis, photochemical synthesis, DNA binding, and antitumor evaluation. Bioorg Med Chem 2006; 14: 2859-2868
21 Witter DJ, Belvedere S, Chen L et al. Benzo[b]thiophene-based histone deacetylase inhibitors. Bioorg Med Chem 2007; 17: 4562-4567
22 Romagnoli R, Baraldi PG, Cara CL et al. Synthesis and biological evaluation of 2-(3′,4′,5′-trimethoxybenzoyl)-3-aryl/arylaminobenzo[b]thiophene derivatives as a novel class of antiproliferative agents. Eur J Med Chem 2010; 45: 5781-5791
23 Shchekotikhin AE, Glazunova VA, Dezhenkova LG et al. Synthesis and cytotoxic properties of 4,11-bis[(aminoethyl)amino]anthra[2,3-b]thiophene-5,10-diones, novel analogues of antitumor anthracene-9,10-diones. Bioorg Med Chem 2009; 17: 1861-1869
24 Ahmed OM, Mohamed MA, Ahmed RR et al. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines. Eur J Med Chem 2009; 44: 3519-3523
25 Ghorab MM, Radwan MAA, Taha NMH et al. Dapson in Heterocyclic Chemistry, Part I: Novel Synthesis of SulfoneBiscompounds for Antimicrobial and Antitumor Activities. Phosphorus, Sulfur, and Silicon and the Related Elements. 2008. 183. 2891-2905
26 Ghorab MM, Amin NE, El Gaby MSA et al. Dapson in Heterocyclic Chemistry, Part III: Synthesis, Antimicrobial, and Antitumor Activities of Some New Bisheterocyclic Compounds Containing Biologically Active Diphenylsulfone Moiety. Phosphorus, Sulfur, and Silicon and the Related Elements 2008; 183: 2918-2928
27 Ghorab MM, Amin NE, El Gaby MSA et al. Dapson in Heterocyclic Chemistry, Part IV: Synthesis of Some Novel Diphenylsulfones Containing Acetamide, Pyrrolidine, Piperazine, and Thiomorpholine Moieties as Antimicrobial and Antitumor Agents. Phosphorus, Sulfur, and Silicon and the Related Elements 2008; 183: 2929-2942
28 Ghorab MM, Radwan MAA, Taha NMH et al. Dapson in Heterocyclic Chemistry, Part II: Antimicrobial and Antitumor Activities of Some Novel SulfoneBiscompounds Containing Biologically Active Thioureido, Carbamothioate, Quinazoline, Imidazolidine, and Thiazole Moieties. Phosphorus, Sulfur, and Silicon and the Related Elements 2008; 183: 2906-2917
29 Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Nat Cancer Inst 1990; 82: 1107-1112
30 Kato K, Cox AD, Hisaka MM et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992; 89: 6403-6407
31 Johnston SR, Ellis PA, Houston S et al. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2000; 19: 83a
32 Karp JE, Lancet JE, Kaufmann SH et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97: 3361-3369
33 Kies MS, Clayman GL, El-Naggar AK et al. Induction therapy with SCH 66336, a farnesyltransferase inhibitor in squamous cell carcinoma (SCC) of the head and neck. Proc Am Soc Clin Oncol 2001; 20: 225a
34 Jonathan C, Toulas C, Ader I et al. The Farnesyltransferase Inhibitor FTI-277 Suppresses the 24-kDa FGF2-Induced Radioresistance in HeLa Cells Expressing Wild-Type RAS. Radiat Res 1999; 152: 404-411
35 Bernhard EJ, McKenna WG, Hamilton AD et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 1998; 58: 1754-1761
36 Bernhard EJ, Kao G, Cox AD et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 1996; 56: 1727-1730
37 Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell 2005; 18: 263-272
38 Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell 2009; 33: 1-13
39 Tang J, Frankel A, Cook RJ et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 2000; 275: 7723-7730